Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Aug;77(15):8448-61.
doi: 10.1128/jvi.77.15.8448-8461.2003.

Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments

Affiliations

Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments

Sally L Painter et al. J Virol. 2003 Aug.

Abstract

Women infected with clade A human immunodeficiency virus type 1 harbor a virus population that is genetically diverse in the envelope gene, a fact that contrasts with the homogeneous virus population identified in newly infected men. It is not known whether viral genetic diversity at this early stage of infection is manifested as phenotypic diversity. This is a significant question because phenotypic diversity in the viral population that establishes infection in women may have important implications for pathogenesis and therapeutic intervention. Thus, in this study we compared the biological properties of three pairs of chimeric viruses that contained envelope genes representative of variant groups in each of three infected women-Q23, Q45, and Q47. Envelope chimeras were evaluated for replication in stimulated and resting peripheral blood mononuclear cells alone and in competition, for coreceptor use, and for neutralization sensitivity. All viruses utilized CCR5 exclusively and had a non-syncytium-inducing phenotype on MT-2 cells and in primary culture. There were no significant differences in replication parameters between paired variants in individual cultures. However, in competition experiments, one chimera of each variant pair always dominated. The dominant virus from Q23 and Q47, but not from Q45, infected a significantly higher number of CCR5- and CD4-expressing GHOST cells than the weaker chimeras. Significantly, chimeric viruses from Q47 and Q45 showed markedly different neutralization sensitivity to antibodies to CCR5 and gp120, respectively. These data indicate that distinct envelope genotypes identified in clade A-infected women near seroconversion confer unique phenotypes that affect viral fitness and that may be due, in part, to different requirements for relative configuration of CD4 and CCR5 on infected cells.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Alignments of the full-length envelope glycoproteins used in chimera construction. (A) Q23; (B) Q45; (C) Q47. Amino acids are given in single-letter codes. Gaps (-) are included to maintain the alignment. Amino acid identity between the two sequences is indicated with a dot (.). Potential N-linked glycosylation sites that differ between the chimera pairs are underlined and in boldface. Locations of variable loops and the gp120/gp41 cleavage site are indicated above the sequence.
FIG. 1.
FIG. 1.
Alignments of the full-length envelope glycoproteins used in chimera construction. (A) Q23; (B) Q45; (C) Q47. Amino acids are given in single-letter codes. Gaps (-) are included to maintain the alignment. Amino acid identity between the two sequences is indicated with a dot (.). Potential N-linked glycosylation sites that differ between the chimera pairs are underlined and in boldface. Locations of variable loops and the gp120/gp41 cleavage site are indicated above the sequence.
FIG. 1.
FIG. 1.
Alignments of the full-length envelope glycoproteins used in chimera construction. (A) Q23; (B) Q45; (C) Q47. Amino acids are given in single-letter codes. Gaps (-) are included to maintain the alignment. Amino acid identity between the two sequences is indicated with a dot (.). Potential N-linked glycosylation sites that differ between the chimera pairs are underlined and in boldface. Locations of variable loops and the gp120/gp41 cleavage site are indicated above the sequence.
FIG. 2.
FIG. 2.
Summary of clade A HIV-1 chimera daily growth rates in stimulated cells from different donors. (A) Q23; (B) Q45; (C) Q47. The daily growth rate was determined from the slope of log p24gag versus day plots. The numbers on the x axis indicate an individual donor, and the virus concentrations used to initiate infection is given in parentheses. Data from donor 1 are not shown in panel A because Q23B6 was not included in those experiments. A different set of donor cells was used for each of the virus pairs (e.g., donor 3 in Q23 experiments is not the same as donor 3 in experiments using Q45 or Q47). The mean daily growth rate is shown as the dashed line for Q23B6 (1.76), Q45D6 (2.48), and Q47S6 (2.19) and a dotted line for Q23A4 (1.73), Q45D5 (2.22), and Q47 M1 (2.05).
FIG. 3.
FIG. 3.
Replication success of clade A HIV-1 chimeras in stimulated or resting cells in individual cultures. A virus was determined to successfully infect a culture under specified conditions if p24gag was detectable at day 12 PI by antigen ELISA. R, resting cells; S, cells stimulated by PHA. The number in parentheses is the total amount of viral p24gag in the inoculum in nanograms per milliliter. Q23 chimeras are included in the indicated treatment categories, although the actual amount of virus in the categories indicated by S (0.5), S (1), and S (5) was 0.3 to 0.6, 3, and greater than 10 ng/ml, respectively.
FIG. 4.
FIG. 4.
Replication success of clade A HIV-1 chimeras in stimulated or resting donor cells in the presence of a competitor. (A) Q23; (B) Q45; (C) Q47. The percentage of successful replications was determined by dividing the number of experiments in which the viral RNA of a chimera could be identified in the supernatant fraction at day 12 by the total number of experiments conducted under each of the indicated conditions. The proportional representation of the chimera in the inoculum is shown on the x axis. S, experiment conducted in PHA-stimulated cells; R, resting cells. The data displayed for stimulated-cell competition studies in panel A were conducted at 3 ng/ml total virus, whereas data in panels B and C include experiments in which infection was initiated with a total virus concentration of both 1 and 5 ng/ml.
FIG. 5.
FIG. 5.
Change in proportional representation of lower-fitness chimeras during the course of competition experiments. The percent possible change was determined by quantitative HTA from the proportion of the chimera in the inoculum and in the supernatant at day 12. A chimera that represented 20% of the total inoculum could decrease to 0% or increase to 100%. Thus, a virus that constituted 60% of the total virus recovered at day 12 achieved 50% of its potential increase, or if it was not represented at day 12, it achieved 100% of its possible decline. Black, gray, and white bars indicate that the virus was present at 20, 50, and 80% of the inoculum, respectively. The numbers in parentheses in the key indicate the total amount of virus inoculum, with solid bars indicating 1 ng/ml and striped bars indicating 5 ng/ml of total virus.
FIG. 6.
FIG. 6.
Neutralization of clade A chimeras by 2D7. Antibody to CCR5 was incubated with CCR5 expressing GHOST cells prior to virus infection, and infection was initiated with 10 ng of p24gag of each chimera per ml. The number of infected cells was determined by flow cytometry. Data are presented as the percentage of cells infected in the presence of 2D7 compared to cells treated with an isotype control antibody and represent the results of four replicate experiments. Concentrations of 2D7 are given in micrograms per milliliter.
FIG. 7.
FIG. 7.
Neutralization of clade A chimeras by 2G12 and IgG1b12. Virus (10 ng of p24gag per ml) and antibodies (10 μg/ml) were incubated together for 30 min and then applied to CCR5-expressing GHOST cells. The number of infected cells was determined by flow cytometry. Data are presented as the percentage of cells infected in the presence of anti-gp120 antibody compared to cells treated with an isotype control antibody and represent the results of two replicate experiments (three replicates for Q45 chimeras).

Similar articles

Cited by

References

    1. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, and E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958. - PubMed
    1. Bailer, R. T., B. Lee, and L. J. Montaner. 2000. IL-13 and TNF-α inhibit dual-tropic HIV-1 in primary macrophages by reduction of surface expression of CD4, chemokine receptors CCR5, CXCR4 and post-entry viral gene expression. Eur. J. Immunol. 30:1340-1349. - PubMed
    1. Bannert, N., D. Schenten, S. Craig, and J. Sodroski. 2000. The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J. Virol. 74:10984-10993. - PMC - PubMed
    1. Barbas, C. F., III, E. Bjorling, F. Chiodi, N. Dunlop, D. Cababa, T. M. Jones, S. L. Zebedee, M. A. Persson, P. L. Nara, E. Norrby, et al. 1992. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 89:9339-9343. - PMC - PubMed
    1. Bleul, C. C., L. Wu, J. A. Hoxie, T. A. Springer, and C. R. Mackay. 1997. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94:1925-1930. - PMC - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources